Skip to Content
Merck
All Photos(1)

Documents

B-006

Supelco

Butalbital solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Synonym(s):

5-Allyl-5-isobutylbarbituric acid

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C11H16N2O3
CAS Number:
Molecular Weight:
224.26
MDL number:
UNSPSC Code:
41116107
PubChem Substance ID:
NACRES:
NA.24

grade

certified reference material

form

liquid

feature

SNAP-N-SPIKE®, SNAP-N-SHOOT®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

drug control

Narcotic Licence Schedule B (Switzerland); psicótropo (Spain); Decreto Lei 15/93: Tabela IIC (Portugal)

concentration

1.0 mg/mL in methanol

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

forensics and toxicology

format

single component solution

storage temp.

2-8°C

SMILES string

CC(C)CC1(CC=C)C(=O)NC(=O)NC1=O

InChI

1S/C11H16N2O3/c1-4-5-11(6-7(2)3)8(14)12-10(16)13-9(11)15/h4,7H,1,5-6H2,2-3H3,(H2,12,13,14,15,16)

InChI key

UZVHFVZFNXBMQJ-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

General description

Butalbital is a barbiturate often combined with other medications such as acetaminophen or aspirin for the treatment of pain or codeine for headaches. Trade names of several butalbital combinations include Axocet®, Bucet, and Bupap® with acetaminophen and Axotal with aspirin. This certified reference solution is suitable for GC/MS or LC/MS applications in forensic analysis, clinical toxicology or urine drug testing.

Application


  • Butalbital API for Research: Investigates Butalbital as an active pharmaceutical ingredient (API), focusing on its properties and applications in synthesizing complex pharmaceutical formulations, essential for developing new barbiturate-based treatments (Yang et al., 2022).

  • Butalbital Compound Synthesis: Explores the synthesis of Butalbital and its derivatives, underlining its critical role in the development of CNS depressants and its pharmacological potential in neurobiological research (Marmura et al., 2015).

  • Barbiturate Biochemical Research: Focuses on Butalbital′s effects on human platelet aggregation, offering insights into its mechanism of action within the cardiovascular system, which is vital for tailoring barbiturate-based therapies (Sato et al., 2003).

  • Butalbital Pharmacological Studies: Discusses the pharmacological profiling of Butalbital, emphasizing its utility in managing acute pain and headaches, thereby supporting its continued use in clinical settings for migraine and tension headache relief (Mazer-Amirshahi et al., 2014).

  • CNS Depressant Research Chemical: Analyzes Butalbital′s role as a central nervous system depressant, assessing its effectiveness and safety profile, which is crucial for its application in chronic pain management and treatment of cluster headaches (Cutrer et al., 1999).



Legal Information

Axocet is a registered trademark of Fougera Pharmaceuticals Inc.
Bupap is a registered trademark of ECR Pharmaceuticals Co., Inc.
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Signal Word

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Storage Class Code

3 - Flammable liquids

WGK

WGK 1

Flash Point(F)

49.5 °F - closed cup

Flash Point(C)

9.7 °C - closed cup


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Elizabeth Loder et al.
Headache, 43(8), 904-909 (2003-08-28)
The overuse of short-acting barbiturate medications for the acute treatment of headache is a common problem in the United States. Most experts agree that withdrawal from these medications is necessary for subsequent headache treatment to be successful, yet there are
C Pistos et al.
Journal of pharmaceutical and biomedical analysis, 36(4), 737-741 (2004-11-10)
A fast and sensitive high performance liquid chromatography (HPLC) assay was developed on a C18 monolithic column for the simultaneous determination of acetaminophen-caffeine-butalbital in human serum. Serum samples were treated with a solid phase extraction procedure. The analytes were separated
Patrick J Phillips et al.
Environmental science & technology, 44(13), 4910-4916 (2010-06-05)
Facilities involved in the manufacture of pharmaceutical products are an under-investigated source of pharmaceuticals to the environment. Between 2004 and 2009, 35 to 38 effluent samples were collected from each of three wastewater treatment plants (WWTPs) in New York and
Inderpreet Sekhon et al.
American journal of kidney diseases : the official journal of the National Kidney Foundation, 46(4), e55-e58 (2005-09-27)
Glomerular tip lesion and its relation to different glomerular diseases is a subject of controversy. The therapeutic and prognostic clinical implications of glomerular tip lesions are ambiguous. We present a case of glomerular tip lesion associated with nonsteroidal anti-inflammatory drug-induced
Thomas N Ward
Headache, 48(5), 728-728 (2008-05-13)
Two hundred patients who were taking daily symptomatic or immediate relief medications, often in excessive quantities, yet suffering from daily or near daily severe headaches were studied. One hundred and sixteen (58%) of them were also taking concomitant prophylactic medications

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service